What is ND Capital and what does the firm do?

ND Capital is a venture capital firm founded in 2002 (formerly NanoDimension) that invests in disruptive technologies across the life, physical, and data sciences. It invests across the United States and Europe, manages more than $800M in assets under management (AUM) across multiple funds, and operates through teams in Silicon Valley, Switzerland, and the Cayman Islands. It is relevant to founders, co-investors, and researchers who want to understand the firm's focus and geographic reach.

Investment focus

ND Capital's stated core belief is that scientific disciplines will continue to converge, and that some of the biggest breakthroughs will come from that convergence. Practically, that means the firm looks across sectors, stages, and technologies rather than confining itself to a single vertical.

• Life sciences — one of the three named areas of focus.
• Physical sciences — the second named area, consistent with the firm's origins in nanotechnology.
• Data sciences — the third named area, reflecting the convergence thesis.

Because the firm states it invests across stages, it does not present itself as a single-stage specialist. The site does not publish check sizes, stage-by-stage allocation, or sector-level fund breakdowns, so those specifics should be confirmed directly with the firm.

Origins and the convergence thesis

ND Capital was founded by Aymeric Sallin, who encountered nanotechnology while conducting research between the physics and chemistry departments at EPFL in the 1990s. His conclusion — that significant breakthroughs would arise at the nanoscale, and that distinguishing real science from speculation would require deep expertise — became the foundation of the firm. That history explains why a firm named for nanoscale science now describes itself as investing across converging disciplines rather than in a single technology category.

Geographic reach and cross-Atlantic support

The firm invests in both the US and Europe and describes its teams in Silicon Valley, Switzerland, and the Cayman Islands as a way to help portfolio companies "bridge the Atlantic" — attracting capital, talent, and business partners on both sides. Sallin has commuted between Switzerland and Boston/Silicon Valley since 2007, after concluding that Europe offered strong science but the US offered better investment opportunities. For a founder, the practical implication is that ND Capital positions itself as useful for transatlantic expansion, not only for capital.

How the firm says it works

ND Capital states that it operates as one team, with members collaborating to identify and evaluate opportunities and to support portfolio companies. It describes its posture as thinking like company owners and helping build "world-class, impactful, lasting companies," and it names creativity, intellect, passion, respect, and perseverance as values. These are self-descriptions rather than independently verified operating practices; they are most useful as a signal of how the firm wants to be evaluated in conversations with founders.

Track record signals

The site's portfolio section lists portfolio companies alongside a large set of "Alumni" entries, indicating a long history of exits or graduations across both the physical science and life science categories. The page does not itemize which companies are current versus alumni, so a founder or co-investor researching fit should ask for the current portfolio and recent activity directly.

Leadership

Aymeric Sallin is Founder and Chief Executive Officer and founded the firm in 2002. He previously worked as a strategy consultant at Bain & Company and serves on the boards of Crocus Technology, H55, Natron Energy, Tarveda Therapeutics, and Selecta Biosciences. He was an elected member of the World Economic Forum's Young Global Leaders Class of 2013 and of the Swiss Academy of Engineering Sciences (2016), and received the 2007 NSTI Fellow Award and a 2012 EPFL Alumni award.

When ND Capital is the right fit to approach

ND Capital is a plausible fit if your company sits at the intersection of life, physical, or data sciences, if you are building in the US or Europe (or plan to expand across the Atlantic), and if you want an investor with a science-convergence thesis rather than a single-sector mandate. It is a weaker fit if you need a published, stage-specific check size or a purely domestic single-market partner — the site does not disclose those details, so verify them before pitching.